What is a stock summary page? Click here for an overview.
Business Description
Amylyx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03237H1014
Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 89.1 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.12 | |||||
| Beneish M-Score | -9.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -41.8 | |||||
| 3-Year EPS without NRI Growth Rate | -37 | |||||
| 3-Year FCF Growth Rate | -21.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 21.67 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.81 | |||||
| 9-Day RSI | 57.47 | |||||
| 14-Day RSI | 55.12 | |||||
| 3-1 Month Momentum % | -25 | |||||
| 6-1 Month Momentum % | -0.33 | |||||
| 12-1 Month Momentum % | 9.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.67 | |||||
| Quick Ratio | 6.67 | |||||
| Cash Ratio | 6.21 | |||||
| Days Inventory | 103.52 | |||||
| Days Sales Outstanding | 55.7 | |||||
| Days Payable | 30.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.5 | |||||
| Shareholder Yield % | 0.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -42.65 | |||||
| Operating Margin % | -334.07 | |||||
| Net Margin % | -345.36 | |||||
| FCF Margin % | -192.06 | |||||
| ROE % | -109.32 | |||||
| ROA % | -88.16 | |||||
| ROIC % | -1015.62 | |||||
| 3-Year ROIIC % | -1939.02 | |||||
| ROC (Joel Greenblatt) % | -4037.96 | |||||
| ROCE % | -105.35 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.91 | |||||
| PB Ratio | 1.58 | |||||
| Price-to-Tangible-Book | 1.58 | |||||
| EV-to-EBIT | -0.51 | |||||
| EV-to-EBITDA | -0.51 | |||||
| EV-to-Revenue | 1.7 | |||||
| EV-to-Forward-Revenue | 1.84 | |||||
| EV-to-FCF | -0.93 | |||||
| Price-to-Net-Current-Asset-Value | 1.62 | |||||
| Price-to-Net-Cash | 1.76 | |||||
| Earnings Yield (Greenblatt) % | -196.08 | |||||
| FCF Yield % | -50.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amylyx Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 87.371 | ||
| EPS (TTM) ($) | -4.44 | ||
| Beta | -0.29 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | 0.01 | ||
| Volatility % | 133.79 | ||
| 14-Day RSI | 55.12 | ||
| 14-Day ATR ($) | 0.28771 | ||
| 20-Day SMA ($) | 3.50875 | ||
| 12-1 Month Momentum % | 9.49 | ||
| 52-Week Range ($) | 1.575 - 7.27 | ||
| Shares Outstanding (Mil) | 88.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amylyx Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amylyx Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amylyx Pharmaceuticals Inc Frequently Asked Questions
What is Amylyx Pharmaceuticals Inc(AMLX)'s stock price today?
The current price of AMLX is $3.78. The 52 week high of AMLX is $7.27 and 52 week low is $1.58.
When is next earnings date of Amylyx Pharmaceuticals Inc(AMLX)?
The next earnings date of Amylyx Pharmaceuticals Inc(AMLX) is 2025-05-09 Est..
Does Amylyx Pharmaceuticals Inc(AMLX) pay dividends? If so, how much?
Amylyx Pharmaceuticals Inc(AMLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers